The subscription period in Prostatype Genomics AB's rights issue of units begins today

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, HONG KONG, SWITZERLAND, SINGAPORE, SOUTH KOREA, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES BEYOND THOSE REQUIRED UNDER SWEDISH LAW. PLEASE REFER TO “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE.

Today, 9 July 2026, the subscription period begins for Prostatype Genomics AB's ("Prostatype Genomics" or the "Company") rights issue of units (consisting of shares and two series of warrants), with preferential rights for the Company's existing shareholders (the "Rights Issue"). The Rights Issue was resolved by the Board of Directors pursuant to the authorization granted by the Annual General Meeting. The subscription period runs until 23 July 2026, inclusive. The Rights Issue comprises a maximum of approximately SEK 47.4 million and is covered by subscription commitments and underwriting commitments totaling approximately SEK 43.2 million, corresponding to approximately 91.3 percent of the Rights Issue. The purpose of the Rights Issue is to finance the continued Medicare approval process, as well as commercialization activities in the United States and Europe.

Summary of terms in the Rights Issue

• Shareholders who were registered in the share register maintained by Euroclear Sweden AB as of the record date, 7 July 2026, will receive one (1) unit right for each share held on the record date. One (1) unit right entitles the holder to subscribe for one (1) unit. One (1) unit consists of eight (8) shares, two (2) warrants of series TO6 and four (4) warrants of series TO7.
• The Rights Issue comprises a maximum of 59,189,321 units, corresponding to a maximum of 473,514,568 shares, a maximum of 118,378,642 warrants of series TO6 and a maximum of 236,757,284 warrants of series TO7. Upon full subscription in the Rights Issue, Prostatype Genomics will initially receive approximately SEK 47.4 million before deduction of transaction costs.
• The subscription price is SEK 0.80 per unit, corresponding to SEK 0.10 per share. The warrants of series TO6 and series TO7 are issued free of charge.
• The subscription period for the Rights Issue runs until and including 23 July 2026.
• One (1) warrant of series TO6 entitles the holder to subscribe for one (1) new share. The exercise price for warrants of series TO6 warrants will be SEK 0.10 per share, corresponding to both the subscription price per share in the Rights Issue and the share's quota value. Upon full exercise of warrants of series TO6 at the maximum exercise price, the Company may receive approximately SEK 11.8 million before deduction of issue costs.
• One (1) warrant of series TO7 entitles the holder to subscribe for one (1) new share. The exercise period for TO7 is event-driven, based on the receipt of Medicare reimbursement approval. The exercise price shall correspond to 70 percent of the volume-weighted average price of the Company’s share on Nasdaq First North Growth Market during a measurement period of ten (10) trading days preceding the Company’s announcement of approval of the Company’s Medicare application. However, the minimum exercise price will be SEK 0.10 per share and the maximum exercise price will be SEK 0.20 per share. The exercise period will commence no earlier than 1 September 2026 and no later than 7 December 2026. Upon full exercise of warrants of series TO7 at the maximum exercise price, the Company may receive approximately SEK 47.2 million before deduction of issue costs.
• The warrants of series TO6 and series TO7 are expected to be admitted to trading on Nasdaq First North Growth Market in close connection with the registration of the Rights Issue with the Swedish Companies Registration Office (Sw. Bolagsverket) and the conversion of paid subscribed units (BTUs) into ordinary shares and warrants.
• In total, the Rights Issue is covered by subscription commitments and underwriting commitments amounting to approximately SEK 43.2 million, corresponding to approximately 91.3 percent of the Rights Issue. The subscription commitments, amounting to approximately SEK 9.2 million in total, will partly be fulfilled through set-off against outstanding shareholder loans and accrued interest thereon, corresponding to approximately SEK 7.4 million.

Background and use of proceeds
To accelerate the commercialization and marketing of Prostatype Genomics' gene expression test, Prostatype®, in the United States, the Company is awaiting Medicare reimbursement approval. Since submitting its Medicare application, the Company has continuously responded to requests for supplementary information. As the process is subject to regulatory procedures conducted by U.S. authorities, the timing of a decision remains difficult for the Company to estimate. The Company is working closely with Swedish and U.S. legal counsel in the process and held an in-person meeting with representatives of Medicare during the second quarter of 2026. Based on the progress made to date, the Company's assessment is that Medicare approval can reasonably be expected to be obtained during the current year. Once Medicare reimbursement approval has been secured, the Board of Directors believes that Prostatype Genomics will be well positioned to commercialize Prostatype® in the U.S. market.

To finance the above-mentioned development initiatives, as well as the repayment/conversion of outstanding bridge loans and accrued interest, Prostatype Genomics is carrying out the Rights Issue, with a maximum issue volume of approximately SEK 47.4 million (before issue costs of approximately SEK 9.8 million, including cash compensation to underwriters). The net proceeds from the Rights Issue are intended to be used for the following purposes:

• Completion of the Medicare reimbursement approval process.
• Ongoing commercialization activities in the United States and Europe, as well as strengthening the Company's working capital and supporting ongoing operating activities.
• Repayment/conversion of bridge loans and accrued interest, as well as settlement of outstanding trade payables.

The proceeds from the exercise of the warrants of series TO6 and TO7 are intended to finance the continued scaling of the Company's commercialization efforts and organization in the United States, as well as general operating expenses. Assuming full subscription of the Rights Issue and full exercise of all warrants of series TO6 and TO7 at the maximum exercise price, the Company expects the available capital to fund its operations through the fourth quarter of 2027.

Terms for the Rights Issue
The Board of Directors resolved on 29 June 2026, pursuant to the authorization granted by the Annual General Meeting held on 22 June 2026, to carry out the Rights Issue, comprising a maximum of 59,189,321 units, corresponding to 473,514,568 new shares, 118,378,642 warrants of series TO6 and 236,757,284 warrants of series TO7. Existing shareholders of Prostatype Genomics have preferential rights to subscribe for units in proportion to their existing shareholdings. The public is also entitled to subscribe for units in the Rights Issue.

Each (1) existing share in the Company held on the record date, 7 July 2026, entitles the holder to one (1) unit right. One (1) unit right entitles the holder to subscribe for one (1) unit. Each (1) unit consists of eight (8) shares, two (2) warrants of series TO6 and four (4) warrants of series TO7. The subscription price in the Rights Issue has been set at SEK 0.80 per unit, corresponding to SEK 0.10 per new share. The warrants of series TO6 and series TO7 are issued free of charge.

Subscription for units shall take place during the subscription period from 9 July 2026 up to and including 23 July 2026. Unit rights not exercised during the subscription period will lapse and become void. Trading in unit rights is expected to take place on Nasdaq First North Growth Market from 9 July 2026 up to and including 20 July 2026. Trading in paid subscribed units (BTUs) is expected to take place from 9 July 2026 until the Rights Issue has been registered with the Swedish Companies Registration Office (Sw. Bolagsverket), which is expected to occur in early August 2026.

Please note that, for administrative reasons, your bank or nominee may apply an earlier deadline for subscription than 23 July 2026. If you have any questions regarding the applicable deadline, please contact your bank or nominee.

Upon full subscription, the Rights Issue will initially increase the Company's share capital by SEK 47,351,456.80, from SEK 5,918,932.10 to SEK 53,270,388.90, and the total number of shares will increase by 473,514,568 shares, from 59,189,321 shares to 532,703,889 shares. Shareholders who choose not to participate in the Rights Issue will have their ownership diluted by approximately 88.9 percent of the share capital and voting rights, calculated based on the total number of shares outstanding following completion of the Rights Issue. Shareholders who do not participate in the Rights Issue may partially offset the economic dilution by selling their unit rights no later than 20 July 2026.

If all warrants of series TO6 are issued and subsequently exercised, the Company's share capital will increase by an additional SEK 11,837,864.20, to a total of SEK 65,108,253.10, and the number of shares will increase by an additional 118,378,642 shares, to a total of 651,082,531 shares. This corresponds to a dilution effect from the warrants of series TO6 of approximately 12.2 percent.

If all warrants of series TO7 are issued and subsequently exercised, the Company's share capital will increase by an additional SEK 23,675,728.40, to a total of SEK 88,783,981.50, and the number of shares will increase by an additional 236,757,284 shares, to a total of 887,839,815 shares. This corresponds to a dilution effect from the warrants of series TO7 of approximately 26.7 percent.

Directed issue in the event of oversubscription
In the event that the Rights Issue is oversubscribed and persons or entities that have entered into subscription commitments without preferential rights are not allocated units, in whole or in part, to an extent sufficient to fulfil their commitments, the Company intends to resolve on a separate directed issue of units (a so-called over-allotment issue). The terms and conditions of any such directed issue of units will correspond to those of the Rights Issue.

Subscription commitments and underwriting commitments
The Company has received subscription commitments, with and without preferential rights, from a number of existing major shareholders, including members of the Board of Directors, amounting in aggregate to approximately SEK 9.2 million, corresponding to approximately 19.4 percent of the Rights Issue. Of these subscription commitments, approximately SEK 7.4 million is intended to be settled through set-off against outstanding shareholder loans and accrued interest thereon. The remaining amount is intended to be settled in cash. No compensation is payable in respect of the subscription commitments.

In addition, the Company has entered into bottom- and top-down underwriting agreements with Vator Securities AB, on customary terms and conditions, amounting to approximately SEK 34 million, corresponding to approximately 71.9 percent of the Rights Issue, of which approximately SEK 23.9 million (50.6 percent) refers to the bottom underwriting and approximately SEK 10.1 million (21.3 percent) refers to the top-down underwriting. The underwriting commission for both the bottom- and the top-down underwriting commitments amount to 14 percent of the underwritten amount if paid in cash or, alternatively, 16 percent of the underwritten amount if the underwriter elects to receive compensation in the form of units in the Company. Vator Securities AB holds the necessary authorization to act as an underwriter and has entered into separate option agreements with a number of investors regarding the transfer of any units that may be allotted pursuant to the fulfilment of the underwriting commitment.

In total, the Rights Issue is covered by subscription commitments and underwriting commitments amounting to approximately SEK 43.2 million, corresponding to approximately 91.3 percent of the Rights Issue. Neither the subscription commitments nor the underwriting commitment are secured by bank guarantees, blocked funds, pledges or similar arrangements.

Should the underwriter elect to receive the underwriting commission in the form of units, the Board of Directors intends to resolve on a directed issue of such units to the underwriter. The terms and conditions of any such directed issue to the underwriter will correspond to those of the Rights Issue.

Warrants of series TO6
The warrants of series TO6 will be issued free of charge. Each (1) TO6 warrant entitles the holder to subscribe for one (1) new share in the Company. The exercise price for warrants of series TO6 will be SEK 0.10 per share, corresponding to both the subscription price per share in the Rights Issue and the share's quota value.

The TO6 warrants may be exercised for subscription of new shares in Prostatype Genomics during the period from 1 September 2026 up to and including 15 September 2026. The TO6 warrants are intended to be admitted to trading on Nasdaq First North Growth Market. The last day of trading in the TO6 warrants is expected to be 11 September 2026.

Upon full exercise of all TO6 warrants at the maximum exercise price, the Company may receive proceeds of approximately SEK 11.8 million before deduction of transaction costs, which are estimated to amount to a maximum of approximately SEK 0.6 million.

The complete terms and conditions for the TO6 warrants will be available on the Company's website.

Warrants of series TO7
The warrants of series TO7 will be issued free of charge. Each (1) TO7 warrant entitles the holder to subscribe for one (1) new share in the Company. The exercise period for the TO7 warrants is event-driven and is contingent upon the Company obtaining Medicare reimbursement approval.

The exercise price shall correspond to 70 per cent of the volume-weighted average price (VWAP) of the Company's share on Nasdaq First North Growth Market during a measurement period comprising the ten (10) trading days preceding the Company's announcement of Medicare reimbursement approval. However, the exercise price shall not be lower than SEK 0.10 per share and not higher than SEK 0.20 per share.

As the primary alternative, an exercise period of ten (10) trading days shall commence three (3) trading days after the Company has announced, by way of a press release, that its Medicare application has been approved, but no earlier than 1 September 2026 and no later than 7 December 2026.

Alternatively, if approval of the Company's Medicare application has not been announced and no exercise period has been determined within the timeframe set out above, the exercise period shall commence on 7 December 2026 and remain open for ten (10) trading days, up to and including 21 December 2026. In such case, the exercise price shall correspond to 70 per cent of the volume-weighted average price (VWAP) of the Company's share during the ten (10) trading days ending two trading days prior to the commencement of the exercise period on 7 December 2026.

Accordingly, the ten (10) trading day exercise period for the TO7 warrants may commence no earlier than 1 September 2026 and no later than 7 December 2026.

Upon full exercise of all TO7 warrants at the maximum exercise price, the Company may receive proceeds of approximately SEK 47.4 million before deduction of transaction costs, which are estimated to amount to a maximum of approximately SEK 2.2 million.

The TO7 warrants are intended to be admitted to trading on Nasdaq First North Growth Market. The last day of trading in the TO7 warrants is expected to be no later than 17 December 2026.

The complete terms and conditions for the TO7 warrants will be available on the Company's website.

Timeline for the Rights Issue

• Subscription period: 9-23 July 2026.
• Trading in unit rights: 9-20 July 2026.
• Trading in BTUs (paid subscribed units): from 9 July 2026 up to and including the date on which the Rights Issue has been registered with the Swedish Companies Registration Office (Sw. Bolagsverket). The last day of trading in BTUs will be announced in a separate press release following completion of the Rights Issue.
• Press release announcing the outcome of the Rights Issue: around 27 July 2026.
• First day of trading in warrants of series TO6 and TO7: around 14 August 2026.

Information memorandum
An information memorandum containing complete terms and conditions for the Rights Issue is available via the Company’s website (www.prostatypegenomics.com).

Information to investors pursuant to the Swedish Foreign Direct Investment Screening Act (2023:560)
As the Company conducts activities deemed worthy of protection under the Swedish Foreign Direct Investment Screening Act (2023:560), certain investments in the Rights Issue may need to be reviewed by the Inspectorate of Strategic Products (ISP). For more information, please visit the ISP website, www.isp.se, or contact the Company.

Advisors
Navia Corporate Finance AB and Birchtree Advisory AB are financial advisors and Bookrunners in connection with the Rights Issue. Advokatfirman Lindahl is the legal advisor. Vator Securities AB is the issuing agent.

For more information about the Rights Issue, please contact:
Navia Corporate Finance AB
E-mail: info@naviacf.se
Website: www.naviacorporatefinance.com

or

Birchtree Advisory AB
E-mail: jonas.bjorkman@birchtreeadvisory.se
Website: www.birchtreeadvisory.se

For more information about the Company, please contact:
Fredrik Rickman, VD Prostatype Genomics AB
Phone: +46 (0) 73 049 77 01
E-mail: fredrik.rickman@prostatypegenomics.com

Certified Adviser
Tapper Partners AB
Phone: +46 (0) 70 44 010 98
E-mail: ca@tapperpartners.se

About Prostatype Genomics
Prostatype® is a genetic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or non-treatment of prostate cancer. The test was developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.

Important information
The information in this press release does not contain or constitute an offer to acquire, subscribe for, or otherwise trade in shares, warrants, or other securities in Prostatype Genomics. No action has been taken, and no action will be taken, to permit an offer to the public in any jurisdiction other than Sweden. The invitation to interested persons to subscribe for shares in Prostatype Genomics will only be made through the information memorandum that Prostatype Genomics intends to publish before the subscription period commences.

The information in this press release may not be released, published, or distributed, directly or indirectly, in or into the United States, Belarus, Russia, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, or any other jurisdiction where such action would be unlawful, subject to legal restrictions, or require measures other than those required under Swedish law. Actions in violation of these restrictions may constitute a violation of applicable securities laws. No shares or other securities in Prostatype Genomics have been registered, and no shares or other securities will be registered, under the United States Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any state or other jurisdiction in the United States, and may not be offered, sold, or otherwise transferred, directly or indirectly, in or into the United States except pursuant to an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with the securities laws of the relevant state or other jurisdiction in the United States. This press release is distributed and directed only to persons in the United Kingdom who are (i) investment professionals within the meaning of Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), or (ii) high net worth entities and other persons to whom this press release may lawfully be communicated, falling within Article 49(2)(a)-(d) of the Order (all such persons together being referred to as “Relevant Persons”). Persons who are not Relevant Persons must not act on or rely on the information contained in this press release. Any investment or investment activity to which this press release relates is available only to Relevant Persons and will only be engaged in with Relevant Persons. Persons distributing this communication must satisfy themselves that such distribution is lawful.

Forward-looking statements
This press release contains forward-looking statements concerning the Company’s intentions, assessments, or expectations regarding the Company’s future results, financial position, liquidity, development, prospects, expected growth, strategies, and opportunities, as well as the markets in which the Company operates. Forward-looking statements are statements that do not relate to historical facts and may be identified by the use of terms such as “believes,” “expects,” “anticipates,” “intends,” “estimates,” “will,” “may,” “assumes,” “should,” “could,” and, in each case, their negative forms, or similar expressions. The forward-looking statements in this press release are based on various assumptions, many of which are in turn based on further assumptions. Although the Company believes that the assumptions reflected in these forward-looking statements are reasonable, there can be no assurance that they will materialize or prove to be correct. Because these assumptions are based on assumptions or estimates and are subject to risks and uncertainties, actual results or outcomes may differ materially from those expressed in the forward-looking statements for a variety of reasons.

Such risks, uncertainties, unforeseen events, and other significant factors may cause actual events to differ materially from the expectations expressed or implied in this press release through the forward-looking statements. The Company does not guarantee that the assumptions underlying the forward-looking statements in this press release are correct, and readers of this press release should not place undue reliance on the forward-looking statements contained herein. The information, opinions, and forward-looking statements expressed or implied in this press release speak only as of the date of this press release and are subject to change. Neither the Company nor any other party undertakes to review, update, confirm, or publicly announce any revision to any forward-looking statement to reflect events that occur or circumstances that arise in relation to the contents of this press release, except as required by law or the Nasdaq First North Growth Market Rulebook for Issuers.